Results 151 to 160 of about 653,512 (354)

The role of circular RNAs in regulating cytokine signaling in cancer

open access: yesFEBS Open Bio, EarlyView.
Cytokines present in the tumor microenvironment fuel cancer development. Aberrant expression of circRNAs contributes to cancer progression. Cytokines are involved in regulating circRNA biogenesis. Furthermore, aberrantly expressed circRNAs regulate the expression of ligands, receptors, and downstream effectors involved in cytokine signaling to promote ...
Vandana Joshi   +4 more
wiley   +1 more source

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

open access: yesFEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa   +13 more
wiley   +1 more source

New mucosal dosage form of insulin.

open access: bronze, 1981
Masami Ishida   +3 more
openalex   +2 more sources

Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity

open access: yesFEBS Open Bio, EarlyView.
This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang   +6 more
wiley   +1 more source

Discriminatory features of dosage form and package.

open access: bronze, 1986
MASAYASU SUGIHARA   +2 more
openalex   +2 more sources

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

open access: yesFEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy